Genetically Modified Pig Kidney Keeps US Man Off Dialysis for Record 9 Months

In a groundbreaking medical milestone for modern healthcare, a genetically modified pig kidney successfully kept a 66-year-old American man suffering from end-stage renal disease off dialysis for a record nine months before he ultimately received a compatible human donor kidney. Published in the prestigious medical journal The Lancet, this landmark case represents the world's first reported clinical transition from a pig kidney xenotransplant to a successful human kidney transplant.The remarkable achievement offers fresh hope to thousands of patients worldwide trapped on prolonged waiting lists due to the severe global shortage of human organs.Pioneering Surgery and The Journey of Patient Tim AndrewsThe patient, Tim Andrews from New Hampshire, USA, suffered from advanced kidney failure linked to type 2 diabetes, facing a bleak statistical prognosis with only a nine percent chance of securing a human donor kidney within five years. In January 2025, a medical team at Mass General Brigham in Massachusetts performed a pioneering xenotransplant, utilizing a kidney harvested from a genetically modified Yucatan miniature pig affectionately named Wilma.The animal organ functioned seamlessly inside Andrews' body for 271 days, granting him a miraculous return to normal daily life—enabling him to cook, vacuum, and take long walks with his dog, Cupcake—before the organ eventually experienced progressive blood vessel damage and functional decline.Precision Gene Editing and Safety ProtocolsBefore the groundbreaking procedure, the donor pig's genome underwent 69 precise genetic edits designed to maximize compatibility with the human immune system, minimize the risk of organ rejection, and eliminate latent porcine viruses that could pose public health hazards.Following the eventual removal of the pig kidney, Andrews spent several months on dialysis before receiving a human organ from a deceased donor. Crucially, post-transplant evaluations revealed no development of new antibodies against human tissue, confirming that the prior xenograft did not complicate the subsequent human transplant, with no porcine pathogens detected at any stage of the clinical journey.Future Prospects for Xenotransplantation and Organ ShortagesMedical experts hail the outcome as a monumental step forward in addressing the chronic global organ shortage.Dr. Leonardo Riella from Mass General Brigham emphasized that xenotransplantation holds immense potential to serve initially as a vital "bridge" therapy to rescue patients from dialysis while they wait for human donors, and potentially as a standalone destination therapy once long-term safety is established. While researchers caution that this success is based on a single patient and requires extensive clinical trials before broader adoption, pioneering medical breakthroughs like this pave the way for a transformative future in transplant medicine.